Celia Hart

Celia HART is Partner at Supernova Invest, third largest and historic investor in Algaia.

Celia Hart is Supernova Invest’s representative on the board of Algaia.

Celia has more than 20 years of experience in the chemical and biotechnology sector. She joined CEA Investissement (now Supernova Invest) in 2005 and has since carried out the investments in several companies operating mainly in life sciences. She serves (or has served) on the Boards of several companies including Algaia, Bioaxial, Diabeloop, Fermentalg, Keranova, Uromems and Theranexus.

Prior to that Celia mainly worked for Cambridge Antibody Technology one of the most

successful UK biotechnology companies (now Medimmune following its acquisition by Astra Zeneca) holding different managing and product development positions including Head of Lead Optimization. She was involved in the development of several therapeutic antibodies in including some in collaboration with international biotechnology or pharmaceutical partners.

Celia holds a degree in Chemistry from the University of Geneva (Switzerland), a Ph.D. from the University of Oxford (UK) and an MBA from Grenoble Ecole de Management (France).